## Screening for haemochromatosis: prevalence among Da

Journal of Internal Medicine 230, 265-270 DOI: 10.1111/j.1365-2796.1991.tb00441.x

Citation Report

#	Article	IF	Citations
1	Screening for Hemochromatosis. New England Journal of Medicine, 1993, 328, 1616-1620.	13.9	242
2	8 Genetics of haemochromatosis. Best Practice and Research: Clinical Haematology, 1994, 7, 903-918.	1.1	27
3	Screening for hemochromatosis: A cost-effectiveness study based on 12,258 patients. Gastroenterology, 1994, 107, 453-459.	0.6	94
4	Testing for Haemochromatosis in the Diabetic Clinic. Annals of Clinical Biochemistry, 1995, 32, 521-526.	0.8	27
5	lron status in young Danish men and women: a population survey comprising 548 individuals. Annals of Hematology, 1995, 70, 215-221.	0.8	20
6	Distinction Between Homozygous and Heterozygous Subjects with Hereditary Haemochromatosis Using Iron Status Markers and Receiver Operating Characteristic (ROC) Analysis. Clinical Chemistry and Laboratory Medicine, 1995, 33, 95-8.	1.4	2
7	A Strategy for Cloning the Hereditary Hemochromatosis Gene. Blood Cells, Molecules, and Diseases, 1995, 21, 207-216.	0.6	7
8	Screening blood donors for hereditary hemochromatosis: Decision analysis model based on a 30-year database. Gastroenterology, 1995, 109, 177-188.	0.6	146
9	Mutation Analysis in Hereditary Hemochromatosis. Blood Cells, Molecules, and Diseases, 1996, 22, 187-194.	0.6	377
10	Population Screening for Haemochromatosis: A Unifying Analysis of Published Intervention Trials. Journal of Medical Screening, 1996, 3, 178-184.	1.1	62
11	HLA-H Mutations in the Ashkenazi Jewish Population. Blood Cells, Molecules, and Diseases, 1997, 23, 95-98.	0.6	34
12	Prevalence of hemochromatosis among first-time and repeat blood donors in Norway. Journal of Hepatology, 1997, 26, 272-279.	1.8	21
13	Mutations in the MHC class I-like candidate gene for hemochromatosis in French patients. Immunogenetics, 1997, 45, 320-324.	1.2	144
14	The screening, diagnosis and optimal management of haemochromatosis. Alimentary Pharmacology and Therapeutics, 1997, 11, 631-639.	1.9	18
15	Prevalence of hereditary hemochromatosis in a Massachusetts corporation: Is Celtic origin a risk factor?. Hepatology, 1997, 25, 1439-1446.	3.6	66
16	lron status in 268 Danish women aged 18-30 years: influence of menstruation, contraceptive method, and iron supplementation. Annals of Hematology, 1998, 77, 13-19.	0.8	133
17	HFEmutations in patients with hereditary haemochromatosis in Sweden. Journal of Internal Medicine, 1998, 243, 203-208.	2.7	93
18	Hemochromatosis: New Insights in Pathogenesis and Diagnosis Following the Discovery of the Gene. Critical Reviews in Clinical Laboratory Sciences, 1998, 35, 239-273.	2.7	10

TION REI

CITATION REPORT

#	Article	IF	CITATIONS
19	lonizing radiation and genetic risks. Mutation Research - Reviews in Mutation Research, 1998, 411, 129-178.	2.4	47
20	Diagnosis of Hemochromatosis. Annals of Internal Medicine, 1998, 129, 925.	2.0	166
21	Screening Blood Donors for Hereditary Hemochromatosis: Decision Analysis Model Comparing Genotyping To Phenotyping. American Journal of Gastroenterology, 1999, 94, 1593-1600.	0.2	58
22	Hemochromatosis probands as blood donors. Transfusion, 1999, 39, 578-585.	0.8	23
23	A retrospective anonymous pilot study in screening newborns forHFE mutations in Scandinavian populations. , 1999, 13, 154-159.		50
24	Evaluation of a workplace hemochromatosis screening program. American Journal of Preventive Medicine, 1999, 16, 303-306.	1.6	14
25	Inheritance of hemochromatosis: family studies. , 2000, , 15-41.		14
26	Early Detection of Genetic Hemochromatosis: Should All Young Adults Be Offered the Genetic Test?. Genetic Testing and Molecular Biomarkers, 2000, 4, 219-228.	1.7	5
27	Geography ofHFEC282Y and H63D Mutations. Genetic Testing and Molecular Biomarkers, 2000, 4, 183-198.	1.7	265
28	Screening for Hemochromatosis: High Prevalence and Low Morbidity in an Unselected Population of 65,238 Persons. Scandinavian Journal of Gastroenterology, 2001, 36, 1108-1115.	0.6	285
29	Haemochromatosis: Where are all the Patients?. Scottish Medical Journal, 2001, 46, 99-100.	0.7	4
30	Clinically overt hereditary hemochromatosis in Denmark 1948–1985: epidemiology, factors of significance for long-term survival, and causes of death in 179 patients. Annals of Hematology, 2001, 80, 737-744.	0.8	123
31	Severity of iron overload in hemochromatosis: effect of volunteer blood donation before diagnosis. Transfusion, 2001, 41, 123-129.	0.8	29
32	Analysis of haemochromatosis gene mutations in a population from the Mediterranean Basin. Liver, 2001, 21, 233-236.	0.1	32
33	Haemochromatosis gene mutations in a clustered Italian population: evidence of high prevalence in people of Celtic ancestry. European Journal of Human Genetics, 2001, 9, 445-451.	1.4	17
34	Genetic Hemochromatosis, a Celtic Disease: Is It Now Time for Population Screening?. Genetic Testing and Molecular Biomarkers, 2001, 5, 127-130.	1.7	59
35	Benefit of Population-based Screening for Phenotypic Hemochromatosis in Young Men. Scandinavian Journal of Gastroenterology, 2002, 37, 1212-1219.	0.6	21
36	Frequencies of the Hereditary Hemochromatosis Allele in Different Populations. Comparison of Previous Phenotypic Methods and Novel Genotypic Methods. International Journal of Hematology, 2003, 77, 48-54.	0.7	11

	CITATION	CITATION REPORT		
#	Article	IF	CITATIONS	
37	Frequency of the HFE C282Y and H63D mutations in Danish patients with clinical haemochromatosis initially diagnosed by phenotypic methods. European Journal of Haematology, 2003, 71, 403-407.	1.1	14	
38	Liver disease in Europe. Alimentary Pharmacology and Therapeutics, 2003, 18, 54-59.	1.9	17	
39	Targeted screening for hereditary haemochromatosis in high-risk groups. Alimentary Pharmacology and Therapeutics, 2004, 20, 1-14.	1.9	23	
40	Screening for Hemochromatosis in Turkey. Digestive Diseases and Sciences, 2004, 49, 444-449.	1.1	13	
41	Frequency of the C282Y and H63D mutations of the hemochromatosis gene (HFE) in 2501 ethnic Danes. Annals of Hematology, 2004, 83, 654-7.	0.8	44	
42	Screening Primary Care Patients for Hereditary Hemochromatosis with Transferrin Saturation and Serum Ferritin Level: Systematic Review for the American College of Physicians. Annals of Internal Medicine, 2005, 143, 522.	2.0	60	
43	The molecular genetics of haemochromatosis. European Journal of Human Genetics, 2005, 13, 1172-1185.	1.4	91	
44	Frequency of the hemochromatosis HFE mutations C282Y, H63D, and S65C in blood donors in the Faroe Islands. Annals of Hematology, 2005, 84, 146-149.	0.8	20	
45	Screening for Hereditary Hemochromatosis: A Systematic Review for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 2006, 145, 209.	2.0	173	
46	Frequencies of the haemochromatosis gene (HFE) variants C282Y, H63D and S65C in 6,020 ethnic Danish men. Annals of Hematology, 2008, 87, 735-740.	0.8	28	
47	Iron status in young Danes. Evaluation by serum ferritin and haemoglobin in a population survey of 634 individuals aged 14–23 yr. European Journal of Haematology, 1997, 58, 160-166.	1.1	15	
48	Hereditary Hemochromatosis (HFE) genotypes in heart failure: Relation to etiology and prognosis. BMC Medical Genetics, 2010, 11, 117.	2.1	7	
49	Unique frequencies of HFE gene variants in Roma/Gypsies. Journal of Applied Genetics, 2012, 53, 183-187.	1.0	6	
51	Epidemiology, molecular biology, and public health. , 2000, , 103-122.		3	
52	Arvelig hemokromatose - nytten av screening. Norsk Epidemiologi, 2009, 16, .	0.2	1	
53	Iron status in young Danish men and women: a population survey comprising 548 individuals. Annals of Hematology, 1995, 70, 215-221.	0.8	2	